VANTAGE4MB, a project proposed by researchers from the Molecular Biomaterials Group – Rui Pereira (leader) and Helena Azevedo, was recognised in the 4th edition (2025/26) of BIP ACCELERATION – a program aimed at supporting scientists from the University of Porto who wish to test and validate the business model of their idea. The team also includes Jorge Lima and Sofia Lamas from the i3S, and Maria João Gil da Costa, pediatric oncologist from the University Hospital of São João, Porto.
VANTAGE4MB is an in vivo platform that enables a better study of the behaviour of medulloblastoma, an extremely aggressive pediatric brain tumour. This advanced biotechnological tool will allow pharmaceutical and biotechnology companies to test the potential of their compounds and tools in a more authentic way, enhancing the potential to cure this tumour. The goal is for pediatric oncologists to use and combine the best personalised therapies, significantly improving clinical outcomes and, consequently, the patients’ quality and life expectancy. This is a comparatively better solution than others available on the market, as it has lower associated costs and allows for faster and more accurate assessment of each child’s tumour’s specific response to different therapies.” (Rui Pereira)
For the group, winning third place in the BIP ACCELERATION competition is a “crucial first step” toward transforming their scientific project into an “innovative business model.” The prize (2000 €) will be used to accelerate the implementation of the technology, fund intellectual property, and carry out the first preclinical trial.
The three winners also have the opportunity to gain access to the UPTEC program School Startups Foundation. Know more about this edition of the BIP ACCELERATION program
Rui Pereira (4th from the left) together with the 1st and 2nd winners of the 4th BIP ACCELERATION